JP2014520108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520108A5 JP2014520108A5 JP2014514164A JP2014514164A JP2014520108A5 JP 2014520108 A5 JP2014520108 A5 JP 2014520108A5 JP 2014514164 A JP2014514164 A JP 2014514164A JP 2014514164 A JP2014514164 A JP 2014514164A JP 2014520108 A5 JP2014520108 A5 JP 2014520108A5
- Authority
- JP
- Japan
- Prior art keywords
- linear
- branched
- unsubstituted
- alkyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 115
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 86
- 125000003118 aryl group Chemical group 0.000 claims description 78
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- 125000001072 heteroaryl group Chemical group 0.000 claims description 73
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 63
- 239000001257 hydrogen Substances 0.000 claims description 63
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 62
- 125000003342 alkenyl group Chemical group 0.000 claims description 56
- 125000000304 alkynyl group Chemical group 0.000 claims description 55
- 229920006395 saturated elastomer Polymers 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 229940002612 prodrug Drugs 0.000 claims description 29
- 239000000651 prodrug Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 20
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 15
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 125000005265 dialkylamine group Chemical group 0.000 claims description 11
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 10
- -1 methoxy, methyl Chemical group 0.000 claims description 10
- 230000002062 proliferating effect Effects 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000005000 thioaryl group Chemical group 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 1
- ABZCXQGJBVWZBD-UHFFFAOYSA-N n-[3-[4-[5-(pyrrolidine-1-carbonyl)-1h-pyrrol-3-yl]-1,3-thiazol-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2SC=C(N=2)C=2C=C(NC=2)C(=O)N2CCCC2)=C1 ABZCXQGJBVWZBD-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 26
- 238000002441 X-ray diffraction Methods 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- 125000003545 alkoxy group Chemical group 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 239000011737 fluorine Substances 0.000 description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 208000035269 cancer or benign tumor Diseases 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 10
- 150000002780 morpholines Chemical class 0.000 description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 125000004438 haloalkoxy group Chemical group 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000001757 thermogravimetry curve Methods 0.000 description 6
- 125000004001 thioalkyl group Chemical group 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000042838 JAK family Human genes 0.000 description 3
- 108091082332 JAK family Proteins 0.000 description 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- OJWYYSVOSNWCCE-UHFFFAOYSA-N 2-methoxyethyl hypofluorite Chemical compound COCCOF OJWYYSVOSNWCCE-UHFFFAOYSA-N 0.000 description 2
- 0 CC*C1=CC(C2=CN=C(C)*2)=C*1 Chemical compound CC*C1=CC(C2=CN=C(C)*2)=C*1 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N N-ethyl-N-methylamine Natural products CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 2
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000013546 non-drug therapy Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520256P | 2011-06-07 | 2011-06-07 | |
| US61/520,256 | 2011-06-07 | ||
| US201161562700P | 2011-11-22 | 2011-11-22 | |
| US61/562,700 | 2011-11-22 | ||
| US201261640139P | 2012-04-30 | 2012-04-30 | |
| US61/640,139 | 2012-04-30 | ||
| PCT/IB2012/001987 WO2012172438A2 (en) | 2011-06-07 | 2012-06-07 | Compositions and methods for modulating a kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520108A JP2014520108A (ja) | 2014-08-21 |
| JP2014520108A5 true JP2014520108A5 (enExample) | 2015-06-11 |
| JP6054379B2 JP6054379B2 (ja) | 2016-12-27 |
Family
ID=47116110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514164A Active JP6054379B2 (ja) | 2011-06-07 | 2012-06-07 | キナーゼをモジュレートするための組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8937065B2 (enExample) |
| EP (1) | EP2718290B1 (enExample) |
| JP (1) | JP6054379B2 (enExample) |
| CN (1) | CN103717593B (enExample) |
| AU (1) | AU2012270029B2 (enExample) |
| BR (1) | BR112013031121B1 (enExample) |
| CA (1) | CA2837268C (enExample) |
| DK (1) | DK2718290T3 (enExample) |
| ES (1) | ES2585244T3 (enExample) |
| HR (1) | HRP20160879T1 (enExample) |
| HU (1) | HUE028097T2 (enExample) |
| IL (1) | IL229692A (enExample) |
| MX (1) | MX355415B (enExample) |
| PL (1) | PL2718290T3 (enExample) |
| PT (1) | PT2718290T (enExample) |
| WO (1) | WO2012172438A2 (enExample) |
| ZA (1) | ZA201309042B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180088926A (ko) | 2012-07-24 | 2018-08-07 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| WO2017097215A1 (zh) * | 2015-12-07 | 2017-06-15 | 杭州雷索药业有限公司 | 内嵌脲类结构的wnt通路抑制剂 |
| KR102214225B1 (ko) * | 2015-12-07 | 2021-02-10 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | 5원 헤테로시클릭 아미드계 wnt 경로 억제제 |
| MY209468A (en) * | 2018-05-29 | 2025-07-10 | Omeros Corp | Masp-2 inhibitors and methods of use |
| AU2020356575A1 (en) | 2019-09-27 | 2022-04-14 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20220110530A (ko) * | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| WO2021146903A1 (zh) * | 2020-01-21 | 2021-07-29 | 苏州信诺维医药科技股份有限公司 | 一种含氮化合物的晶型 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022251434A1 (en) * | 2021-05-26 | 2022-12-01 | Emory University | Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy |
| MX2024003795A (es) * | 2021-09-29 | 2024-06-03 | Repare Therapeutics Inc | Compuestos de n-(5-sustituido-[(1,3,4-tiadiazolil) o (tiazolil)])(sustituido)carboxamida y uso de estos para inhibir la polimerasa theta humana. |
| KR20250108598A (ko) * | 2022-09-29 | 2025-07-15 | 리페어 세라퓨틱스 인크. | N-(5-치환된-[(1,3,4-티아다이아졸릴) 또는 (1,3-티아졸릴)](치환된)카복스아마이드 화합물, 약제학적 조성물, 그리고 아마이드 화합물의 제조 방법 및 이의 용도 |
| EP4620949A1 (en) * | 2024-03-18 | 2025-09-24 | Eberhard Karls Universität Tübingen (Medizinische Fakultät) | Ackr3 modulators for cardiovascular or antiplatelet therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
| DE3772301D1 (de) * | 1986-08-29 | 1991-09-26 | Pfizer | 2-guanidino-4-aryl-thiazole fuer die behandlung von peptischen geschwueren. |
| US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
| EP1130017B1 (en) * | 1990-11-30 | 2005-06-15 | Otsuka Pharmaceutical Co., Ltd. | Azole derivatives and their use as superoxide radical inhibitors |
| US5578322A (en) | 1990-11-30 | 1996-11-26 | Yamanouchi Pharmaceutical Co., Ltd. | Quick release coated preparation |
| US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US5895664A (en) | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
| US5616344A (en) | 1994-06-14 | 1997-04-01 | Fuisz Technologies Ltd. | Apparatus and process for strengthening low density compression dosage units and product therefrom |
| US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| DE69840495D1 (de) | 1997-02-20 | 2009-03-12 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
| US6277406B1 (en) | 1997-10-08 | 2001-08-21 | Fuisz Technologies Ltd. | Easily processed tablet compositions |
| JP2002531503A (ja) * | 1998-12-07 | 2002-09-24 | スミスクライン・ビーチャム・コーポレイション | Ｍｙｔ１キナーゼ阻害剤 |
| CA2397661C (en) * | 2000-03-01 | 2012-01-03 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
| ATE400571T1 (de) * | 2003-01-02 | 2008-07-15 | Hoffmann La Roche | Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors |
| AU2007290359B2 (en) * | 2006-09-01 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase |
-
2012
- 2012-06-07 WO PCT/IB2012/001987 patent/WO2012172438A2/en not_active Ceased
- 2012-06-07 ES ES12780531.5T patent/ES2585244T3/es active Active
- 2012-06-07 CN CN201280028167.8A patent/CN103717593B/zh active Active
- 2012-06-07 DK DK12780531.5T patent/DK2718290T3/en active
- 2012-06-07 JP JP2014514164A patent/JP6054379B2/ja active Active
- 2012-06-07 BR BR112013031121-5A patent/BR112013031121B1/pt active IP Right Grant
- 2012-06-07 HU HUE12780531A patent/HUE028097T2/en unknown
- 2012-06-07 PT PT127805315T patent/PT2718290T/pt unknown
- 2012-06-07 PL PL12780531.5T patent/PL2718290T3/pl unknown
- 2012-06-07 CA CA2837268A patent/CA2837268C/en active Active
- 2012-06-07 MX MX2013014433A patent/MX355415B/es active IP Right Grant
- 2012-06-07 AU AU2012270029A patent/AU2012270029B2/en active Active
- 2012-06-07 EP EP12780531.5A patent/EP2718290B1/en active Active
- 2012-06-07 HR HRP20160879TT patent/HRP20160879T1/hr unknown
- 2012-06-07 US US13/491,069 patent/US8937065B2/en active Active
-
2013
- 2013-11-28 IL IL229692A patent/IL229692A/en active IP Right Grant
- 2013-12-02 ZA ZA2013/09042A patent/ZA201309042B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520108A5 (enExample) | ||
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AU2015335694B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| AU2015353210B2 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| JP2019517487A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| AU2018338098B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| JP2016509047A5 (enExample) | ||
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2016523973A5 (enExample) | ||
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2011509309A5 (enExample) | ||
| JP2010539095A5 (enExample) | ||
| PH12012501773A1 (en) | Arylethynyl derivatives | |
| JP2014503567A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| JP2020511547A5 (enExample) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов |